Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, E., … Shapiro, J. (2015). 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. In European Journal of Cancer (Vol. 51, pp. S726–S726). Elsevier BV. https://doi.org/10.1016/s0959-8049(15)30078-2

Segelov, E., S. Thavaneswaran, P. Waring, J. Desai, K. Mann, E. Elez, L. Chantrill, et al. “32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.” In European Journal of Cancer, 51:S726–S726. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(15)30078-2.

Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, et al. 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. In: European Journal of Cancer. Elsevier BV; 2015. p. S726–S726.

Segelov, E., et al. “32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S726–S726. Crossref, doi:10.1016/s0959-8049(15)30078-2.

Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Shapiro J. 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European Journal of Cancer. Elsevier BV; 2015. p. S726–S726.